The U.S. Food and Drug Administration has approved Merck & Co.’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph), a subcutaneous injection for adult patients across most solid tumor indications previously approved for KEYTRUDA ( …

Merck & Co., Inc. (NYSE:MRK) is included among the 13 Best High Dividend Stocks to Buy Under $100. Dividend Stability and Market Reach: Merck & Co (MRK) Among Top Dividend Stocks to Buy Under $100 Image by Steve Buissinne from Pixabay Merck & …

Courts have split regarding whether a 2010 amendment to the AKS, which mandates that a “claim that includes items or services resulting from a violation of [the AKS] constitutes a false or fraudulent claim” under the FCA, means that a plaintiff must …

AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with …

LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its …

Eli Lilly and Co. LLY CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices. He warned that patients may miss out on new medicines …

Excitement around Fujifilm Biotechnologies’ massive new cell culture facility in Holly Springs, North Carolina, has been growing steadily since 2021, prompting a beefed-up investment from the company last April and a string of high-profile manufacturing …

Jiangsu Hengrui Pharmaceuticals’ dealmaking spree rolls on, with a potential $1.1 billion transaction on a rival to AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu being the latest addition. Hengrui is licensing certain rights to its HER2 antibody- …

MSD has signed an agreement with Variational AI to use its generative AI (genAI) platform Enki in the discovery of new small-molecule medicines. Vancouver, Canada-based Variational – which emerged in 2021 with seed funding of $3.4 million – will use a …

PORTLAND, KS, UNITED STATES, September 24, 2025 /⁨EINPresswire.com⁩/ -- Nanomedicine Market Trends According to a new report published by Allied Market Research, titled, “Nanomedicine Market by Modality, Application, and Indication: Global …